wiping out teams working on research about adults with cognitive disabilities and sickle cell disease. Work likely to be halted by the cuts includes the collection of data for studying Americans ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's disease (AD ... the brain's resident immune cells, and have identified ...

Among the 31 samples, the average concentration of C-reactive protein was 4.45 mg/L, with no significant differences observed based off SCD genotype or treatment with hydroxyurea. When Dr. Wu and ...

Scientists at Raman Research Institute (RRI) have developed an affordable electro-fluidic device that aids in preliminary screening of Sickle Cell Disease (SCD). According to RRI, the innovative ...

ABC008 has been designed to treat diseases mediated by these Tc cells, including IBM and T-cell large granular lymphocytic leukemia (T-LGLL). IBM and rheumatoid arthritis overlap clinically with ...

Although clear areas of overlap are known to exist between mast cell disorders and eosinophilia, it is seemingly easier to navigate each of these disease entities separately—that is, to address mast ...

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion dependent beta-thalassemia (TDT), positioning Abu Dhabi as a ...

Spots can also look very different depending on your skin tone. Some pink, red, or brown spots are more obvious ... in which the body produces skin cells at a rapid pace, causing them to pile ...

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...

Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, potentially opening a path to new treatments for a condition that kills 80% of ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...